Health Canada Reviews Suicide Risk with GLP-1 Medications

Health Canada has completed a comprehensive safety review examining potential risks of suicide, self-harm and suicidal ideation associated with GLP-1 receptor agonist medications.

Regulatory Safety Assessment

The federal health regulator conducted the review to assess whether Ozempic, Wegovy, Mounjaro and other GLP-1 receptor agonists pose risks related to suicidal thoughts or self-harm behaviors. The review document was published through Health Canada's Drug and Health Product Review Files system.

GLP-1 receptor agonists currently available in Canada include semaglutide products such as Ozempic, Wegovy and Rybelsus from Novo Nordisk, as well as tirzepatide products Mounjaro and Zepbound from Eli Lilly. The safety review covered all medications in this drug class approved for use in Canada.

Background of Safety Concerns

The review follows international discussions about potential psychiatric side effects associated with GLP-1 medications. Regulatory agencies worldwide have been examining reports of mood-related adverse events to determine if there are causal relationships with these medications.

Health Canada's assessment is part of ongoing post-market surveillance activities that monitor the safety profile of all approved medications. The agency regularly reviews emerging safety data and adverse event reports to ensure Canadian patients receive accurate risk-benefit information.

Current Market Context

The safety review comes as millions of Canadians use GLP-1 medications, with recent surveys indicating approximately 3 million Canadian adults currently take these drugs. The market is expected to expand further with generic competition anticipated in mid-2026 following the expiration of key patents.

Nine generic semaglutide applications are currently under Health Canada review, with manufacturers including Sandoz, Apotex, Teva and others preparing to launch lower-cost alternatives. The safety profile of these medications remains a critical consideration as access expands.

Regulatory Framework

Health Canada's review process examines clinical trial data, post-market adverse event reports, and scientific literature to assess potential safety signals. The agency evaluates whether reported events represent genuine safety concerns or occur coincidentally in patient populations.

Patients currently taking GLP-1 medications should consult healthcare providers with any concerns about mood changes or other side effects. The medication FAQ section provides additional information about proper usage and safety considerations.

Insurance and Access Implications

Safety reviews can influence insurance coverage decisions and prescribing guidelines. Provincial drug plans and private insurers monitor Health Canada's safety assessments when determining coverage criteria and prior authorization requirements.

The review's findings may affect how healthcare providers screen patients and monitor for potential adverse effects. This could influence prescription patterns and patient access to these medications across Canadian provinces.

Next Steps

Health Canada has not yet published final conclusions from the safety review. The agency typically issues public communications when safety assessments result in label changes, new warnings, or other regulatory actions.

Healthcare providers and patients await the regulator's formal recommendations on monitoring protocols and risk management strategies. Any resulting label updates would apply to all GLP-1 medications approved in Canada, including future generic versions.

This article is for informational purposes only and does not constitute medical advice.